Subscribe to Axios Markets for the latest on the trade war's impact.


The pharma industry tilt of the FDA

FDA headquarters building in Maryland.
The FDA is rejecting fewer drug applications. Photo: Al Drago/CQ Roll Call via Getty Images

The Food and Drug Administration is "increasingly green-lighting expensive drugs despite dangerous or little-known side effects and inconclusive evidence that they curb or cure disease," due in part to direct and indirect influence from the pharmaceutical industry, ProPublica reports.

The bottom line: The Trump administration says quick drug approvals benefit patients in need. But drug companies are collecting the financial rewards with high-priced medicines and few, if any, incentives to make sure their drugs are effective after they hit the market.